Vaccine composition and stabilisation method
AssigneeAventis Pasteur Limited
InventorsAlain Francon, Catherine Noel
Life of this patent
Estimating the term…
Abstract
The invention concerns the stabilisation of a vaccine composition maintained in liquid state by the use of high molecular weight polyvinylpyrrolidone, hence eliminating the use of albumen. The invention is of particular interest for vaccine compositions comprising attenuated live viruses such as oral vaccine against poliomyelitis.
Claims10
Method for stabilizing a vaccine composition in the liquid state, characterized in that it consists in adding, to the vaccine composition, high-molecular-weight polyvinylpyrrolidone.
Method according to the preceding claim, characterized in that the molecular weight is greater than or equal to 100 000.
Method according to one of the preceding claims, characterized in that the concentration of polyvinylpyrrolidone is at least 0.1%.
Method according to the preceding claim, characterized in that the concentration of polyvinylpyrrolidone is less than or equal to 5%.
Method according to one of the preceding claims, characterized in that it consists, in addition, in adding to the vaccine composition magnesium chloride in a substantially molar concentration.
Method according to one of the preceding claims, characterized in that it consists, in addition, in adding to the vaccine composition at least one surfactant at a concentration of less than or equal to 0.007%.
Method according to the preceding claim, characterized in that it consists in adding to the vaccine composition Polysorbate 80 in a concentration equal to 0.004%.
Method according to one of the preceding claims, characterized in that the vaccine composition comprises at least one antigen consisting of an attenuated live virus.
Method according to the preceding claim, characterized in that the vaccine composition comprises the 3 serotypes of the poliomyelitis virus.
Liquid vaccine composition which is stable over time, characterized in that it comprises at least one viral antigen, and at least high-molecular-weight polyvinylpyrrolidone.
Dependencies are inferred from the claim text.